Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Sales (2020 - 2025)

Foghorn Therapeutics has reported Return on Sales over the past 6 years, most recently at 2.4% for Q4 2025.

  • Quarterly results put Return on Sales at 2.4% for Q4 2025, up 443.0% from a year ago — trailing twelve months through Dec 2025 was 2.51% (up 132.0% YoY), and the annual figure for FY2025 was 2.51%, up 132.0%.
  • Return on Sales for Q4 2025 was 2.4% at Foghorn Therapeutics, down from 2.02% in the prior quarter.
  • Over the last five years, Return on Sales for FHTX hit a ceiling of 0.82% in Q3 2023 and a floor of 652.68% in Q3 2021.
  • Median Return on Sales over the past 5 years was 5.11% (2023), compared with a mean of 46.4%.
  • Biggest five-year swings in Return on Sales: crashed -54826bps in 2021 and later surged 64880bps in 2022.
  • Foghorn Therapeutics' Return on Sales stood at 39.98% in 2021, then surged by 83bps to 6.9% in 2022, then skyrocketed by 39bps to 4.18% in 2023, then crashed by -63bps to 6.83% in 2024, then soared by 65bps to 2.4% in 2025.
  • The last three reported values for Return on Sales were 2.4% (Q4 2025), 2.02% (Q3 2025), and 2.49% (Q2 2025) per Business Quant data.